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rapid recovery of cardiac output (following lung aeration) increas-
es the risk of cerebral vascular injury.[10] Waiting with cord 
clamping until the infant is stable and breathing (physiological 
based cord clamping) has been shown to be safe and feasible. [11] 
Less bradycardia and hypoxia was observed, supporting the more 
stable hemodynamic transition described in the animal studies.
[11] Currently, large trials in preterm infants are underway to in-
vestigate whether physiological based cord clamping improves im-
portant clinical outcome when compared to time-based cord 
clamping. 
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Cardiopulmonary Transition of Preterm Infants 
at Birth: Optimal Strategies for Support and 
Stabilization 
A. te Pas 
Department of Pediatrics, Leiden University Medical Center, 
Leiden, The Netherlands
During the transition to life after birth, lung aeration is pivotal 
for the changes in respiratory and cardiovascular function that are 
required for survival.[1] However, our understanding of factors 
controlling breathing in preterm infants at birth is limited and so 
our ability to optimize non-invasive strategies to support the 
transition from fetal to newborn life is limited. Most preterm 
infants fail to aerate their immature lungs and need respiratory 
support [2] and cord clamping then compromises cardiovascular 
function. This can have severe consequences for the infant as even 
short periods of inappropriate support can induce lung and brain 
injury.[3]
To minimize injury, non-invasive ventilation strategies (NIV; 
positive pressure support of breathing and/or ventilation via face-
mask) are now universally adopted as the first choice for respira-
tory support at birth.[2, 4] However, little is known about how they 
interact and integrate with the infant’s changing physiology. While 
we assumed that the applied pressure is transmitted into the tra-
chea, this assumption now appears to be incorrect.[5, 6] In new-
borns with a unstable breathing pattern at birth, the larynx is ad-
ducted and only briefly opens during a breath. [7] There is a need 
for strategies that stimulate and support breathing and avoid fac-
tors that impede or inhibit breathing to optimize the success of 
NIV at birth.
Based on the rationale that a preterm infant can benefit from a 
placental transfusion, cord clamping is now delayed for 30-60 
seconds if the clinical condition of the infant allows it.[8] How-
ever, this time-based cord clamping approach does not take into 
account whether the infant has aerated their immature lungs. Cord 
clamping before the infant commenced air-breathing greatly re-
duces the infant’s cardiac output at birth, which increases the risk 
for hypoxic ischemic injury.[9, 10] Also, the sudden loss and then 
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Management of the Severely Compromised  
Term Infant
C.C. Röhr
Newborn Services, John Radcliffe Hospital, Oxford University 
Hospitals, NHS Foundation Trust, University of Oxford,  
Oxford, UK
Attending severely compromised newborn babies who are in 
need of intervention at birth can be a highly challenging task. 
Incomplete adjustment at birth, resulting in significant cardio-
respiratory compromise may have many causes which are not 
always imminently apparent. International newborn resuscitation 
guidelines advise on certain aspects of resuscitation, particularly 
advising a focus on airway-breathing-circulation algorithms [1–3]. 
However, different to the preterm population where measures of 
support of their fetal-to-neonatal transition have been in the 
spotlight of much translational research, far less certainty from 
higher grade evidence is currently available to guide term born 
resuscitation. 
In this paper, a review of the evidence-base of common 
interventions applied during term-born resuscitation is given. We 
suggest that an in-depth understanding the normal physiology of 
fetal-to-neonatal transition is mandatory as this will help with 
understanding and tackling the pathophysiology of common 
reasons for term-born infants’ compromise [4]. Such knowledge 
also will assist with planning resuscitation of compromised term 
newborn infants. Whilst immediate provision of advanced life 
support is necessary, it is important to act on as much evidence as 
possible to be effective and at the same time limit the potential for 
iatrogenic, long-term harm. Below, the latest evidence synthesis 
for specific resuscitative measures will be given and areas of 
urgently needed research be highlighted. 
For resuscitation of infants born at or near term, newly emerg-
ing evidence points towards benefits of initiating resuscitation 
whilst delaying umbilical cord clamping [4, 6]: As shown by in a 
large scale clinical trial by Andersson et al., including over 1500 
late preterm and term born infants, resuscitation with an intact 
umbilical cord improved SpO2 and resulted in higher Apgar scores, 
in absence of negative infant or maternal consequences [6]. This 
information adds significantly to the already well-established ben-
efits of delaying cord clamping in non-compromised infants [7]. 
Further certainty was gained over the past five years regarding 
managing the infant born through meconium-stained amniotic 
fluid. Comprehensive review of the most recent data from ran-
domised clinical trials by the ILCOR (international liaison com-
mittee on resuscitation) neonatal task force has led to a suggestion 
of change in practice, advising for immediate commencement of 
respiratory support and against routine immediate direct laryn-
goscopy after delivery [9]. For commencing respiratory support, 
high certainty exists regarding the advised initial oxygen concen-
tration for term born infant, compared to lesser certainty for pre-
term infants. For the infant born at or above 35 weeks gestation, 
sufficient evidence exists to strongly advise for a starting fraction 
of inspired oxygenation (FiO2) of 0.21 [1, 5]. When applying ad-
ditional oxygen during stabilisation, it is advised to monitor oxy-
genation by pulse oximetry and taper the fraction of inspired oxy-
gen against published nomograms [1].
Maintaining normothermia during initial resuscitation is vital 
in order to minimise morbidity and mortality. Thus, therapeutic 
hypothermia should not be initiated during the immediate resus-
citation as it remains a targeted treatment for infants with signs of 
encephalopathy [9].
Whilst it is acknowledged that the long-term outcomes of even 
severely depressed newborns with Apgar-scores of zero is not nec-
essarily catastrophic, it seems prudent to have a local resuscitation 
protocol which includes a sensible approach towards curtailing re-
suscitative efforts if shown to be futile [10]. Team management, 
including routine pre-resuscitation preparation and structured 
debriefing are becoming more acceptable practice.
A varying, often significant degree of uncertainty remains re-
garding most other interventions for and devices used during new-
born resuscitation. These include methods of heart rate assess-
ment, incl. pulseless electrical activity [11], resuscitation drugs 
incl. use of adrenaline (epinephrine) and fluid therapy [12], central 
vascular access (other than umbilical vein catherization) [13], and 
supraglottic airways [14], and adjunct technologies, for instance 
for assessing intubation success and means to measure effective 
ventilation [15], pneumothorax drainage or ultrasound imaging 
(ECHO) to assess haemodynamic function during cardiovascular 
collapse [16]. 
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Neonatal Oxygen Exposure and Optimal Oxygen 
Saturations: Do We Have the Answer Yet?
O.D. Saugstad
Department of Pediatric Research, University of Oslo, Oslo, 
Norway and Ann and Robert H. Lurie Children’s Hospital of 
Chicago, Northwestern University, Feinberg School of Medicine, 
Chicago, IL, USA
For 200 years newborn infants in need of stabilization/resusci-
tation at birth were given 100% O2. It was not until 40 years ago 
this practice was challenged, and it took another 30 years before it 
was changed. In 2010 the International Liaison Committee on Re-
suscitation (ILCOR), changed recommendations to start with air 
in term and near term infants and the use of an oxygen blender to 
use oxygen judiciously in preterm infants. The reason was that 
multicenter studies and meta analyses had shown excess mortality 
if the procedure started with 100% O2. Further, hyperoxia also de-
layed the time to the first breath approximately 30 seconds [1-3].
However, the last 10 years or so it has become less clear which 
FiO2 is optimal to start out with in premature infants < 32 weeks 
GA and especially the most immature (<28 weeks GA or less) [4].
The following questions are among the most burning in con-
temporary neonatology:
How much O2 (assessed by FiO2, SpO2) do immature infants 
need for stabilization the first 5-10 minutes after birth?
What is the optimal SpO2 increase the first 5-10 minutes of life?
Is there any long term consequences by giving even a brief ini-
tial pulse of high FiO2 ?
Should we start high or low and titrate according to the SpO2 
development?
Data how SpO2 develops in term non-asphyxic babies the first 
minutes of life are well established, however data regarding 
immature babies are much less reliable. Recently we published data 
demonstrating that for newborn infants < 32 weeks GA there was 
no difference in outcome whether initial FiO2 was 0.21 or 1.00. 
However, for infants < 28 weeks GA mortality is higher if initial 
FiO2 is 0.21 compared to 1.00 (RR 3.9 (95% CI 1.1-13.4) [3]. 
Further, we have shown that infants with GA between 28 and 32 
weeks outcome is worse if SpO2 at 5 min does not reach 80% or 
more (mortality OR 2.4, 95% CI 1.3-4.4), severe IVH OR 4.5, 95% 
CI 2.1-9.8) [5, 6]. Although this may reflect that infants not 
reaching a saturation of 80% within 5 minutes of life is sicker than 
those who do, recommendations at the present stage is to achieve 
a SpO2 of 80-85% within 5 minutes of life.
 How and when to adjust FiO2 to reach this goal is not settled. 
Data indicate that not before 2-3 minutes of life there is a significant 
separation in SpO2 between those who reach and do not reach 80% 
within 5 minutes of life. This means the clinician has 1-2 minutes 
only to make proper adjustments. The question is therefore 
whether it is better to start high, with an initial FiO2 of 0.6-1.0 or 
start low with an initial FiO2 of 0.3. In both cases FiO2 should be 
titrated to keep SpO2 within recommended targets. We know that 
even a brief pulse of hyperoxia to newborns increases oxidative 
stress and inflammatory reactions which may last for days and 
even weeks and perhaps longer. We therefore suggest to start low 
and titrate FiO2 up according to the needs. However, this question 
is presently not yet solved.
Even a brief exposure to 60-100% O2 also triggers genomic 
changes. Newborn mice exposed to hyperoxia for days also have 
epigenetic changes which may last life-long. Exposure to hyper-
oxia immediately after birth therefore may trigger consequences 
for adult life and perhaps represent a risk factor for developing 
degenerative diseases later in life.
Conclusion: The last 10 years the oxygen load to newborns in 
need of ventilation and stabilization in the delivery room has been 
reduced substantially. Still, we don’t know how premature and es-
pecially immature infants should be oxygenated. The consequenc-
es of too low or too high oxygen exposure at birth may be life-long. 
Continuous research in this area therefore is among the most im-
portant in present neonatology.
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Nasal CPAP: The Gold Standard in Non-Invasive 
Support
R.A. Polin 
Columbia University College of Physicians and Surgeons, New 
York, NY, USA
Despite the many advancements in neonatal medicine, includ-
ing the widespread use of surfactant, the incidence of bronchopul-
monary dysplasia (BPD) has not substantially decreased over 












































































incidence of BPD include vitamin A, caffeine, postnatal steroids 
and continuous positive airway pressure (CPAP) [1]. Surprisingly, 
neither surfactant nor antenatal steroids have had a significant im-
pact on the incidence of BPD. The benefits of using CPAP as first 
line therapy has been demonstrated in multiple clinical trials in 
which intubation and surfactant have been compared to non-in-
vasive application of CPAP. Meta-analyses from these trials indi-
cate that the use of CPAP significantly decreased the combined 
outcome of death or BPD [2]. However, the benefits of CPAP are 
modest with an estimated risk ratio of 0.90 (CI 0.83-0.98). Why has 
CPAP been only marginally better in the randomized clinical tri-
als? There are four possible reasons. First of all, CPAP looks decep-
tively simple, but inexperienced usage of CPAP at the centers in 
the trials may have been a significant contributing factor. Success-
ful implementation of CPAP requires experienced physicians, 
nurses and respiratory therapists. Data from Aly et al at George 
Washington University suggest that it may take more than a year 
after CPAP is introduced to see a reduction in the incidence of 
BPD [3]. Secondly, many of the infants randomized to the CPAP 
arm in these trials were intubated and received surfactant when 
they met failure criteria. Therefore, the trials did not actually com-
pare intubation and surfactant with infants who were successfully 
maintained on CPAP. Thirdly, the duration of mechanical ventila-
tion was so short in these trials (1-2 weeks) that it would have been 
difficult to show a reduction in the incidence of BPD. Finally, a 
variety of CPAP devices were used and the mode of delivery of 
CPAP may determine its efficacy. CPAP can be delivered using a 
mechanical ventilator with a threshold resistance exhalation valve, 
using a bubble CPAP (bCPAP) device or a variable flow nasal 
CPAP device (e.g., infant flow driver). Small randomized clinical 
trials suggest that CPAP delivered using a mechanical ventilator 
may not be as effective as bCPAP or a variable flow device. Gupta 
et al compared bCPAP with infant flow driver (a variable flow de-
vice) and showed that bCPAP decreased the risk of post extubation 
failure [3]. Experimental animal studies comparing CPAP delivery 
system suggest that bCPAP increases airway patency improving 
oxygen extraction and ventilation [4].
Optimal levels of CPAP when used non-invasively are contro-
versial. Observational data from preterm infants suggest that most 
infants achieve adequate oxygenation with pressures ranging from 
4-6 mm Hg. Higher pressures (up to 8 mm Hg) may occasionally 
be needed, but the safety of higher CPAP pressures is uncertain. 
Higher CPAP pressures, when used non-invasively) have not been 
associated with adverse effects on hemodynamics or impaired ven-
tilation. It is important to remember that infants failing CPAP of-
ten fail for mechanical reasons related to the CPAP delivery sys-
tems and not because of inadequate pressure.
Equally controversial is the best way to wean CPAP. Three 
weaning strategies have been used, gradual reduction of pressure, 
sudden removal of nasal CPAP and sprinting. A meta-analysis did 
not demonstrate the benefit of any one weaning strategy. However, 
a recent randomized clinical trial by Jensen et al suggested that 
pressure weans were more effective than “sudden” weans in infants 
< 28 weeks gestation [5]. Our criteria for weaning include:
• > 30 weeks post menstrual age
• No supplemental oxygen for at least 48 hours
• Asymptomatic PDA
• No bradycardia or desaturation requiring intervention
• ≤ 2 self-limited bradycardia or desaturation episodes in the pri-
or 12 hours
• ≥ 90% saturation in 21% FiO2
• Free of infection
Conclusions: 1. Preterm infants with RDS weighing < 1500 
gms. should be allowed time to demonstrate if they can achieve ac-
ceptable ventilation and oxygenation on CPAP. 2. During that 
time period, these infants must be monitored closely. If ventilation 
is not improving (pH < 7.2 and PCO2 > 65) or oxygenation is in-
adequate with an FiO2 of 40%-60%, these infants should be intu-
bated. 3. If it is likely that respiratory support with a ventilator will 
be needed, early administration of surfactant followed by rapid 
extubation, is preferable to prolonged ventilation (LOE 1). 
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Limitations of Noninvasive Ventilation: When is 
Mechanical Ventilation in the Very Immature Infant 
Indicated?
E. Bancalari 
Division of Neonatology, University of Miami Miller School of 
Medicine, Miami, FL, USA 
Invasive respiratory support in preterm infants is associated 
with lung injury and increased incidence of BPD. To avoid these 
complications, several less invasive strategies have been developed 
to support respiratory function and are now used as an alternative 
to mechanical ventilation. The oldest and most common modality 
is Nasal CPAP (NCPAP) that in infants with good respiratory ef-
fort has been shown to be as effective as invasive IPPV but with 
lower incidence of death or BPD. One of the limitations of NCPAP 
without intubation is that it may prevent the use of surfactant in 
infants who can benefit from this therapy. In order to provide the 
beneficial effects of exogenous surfactant and at the same time lim-
it the use of invasive ventilation, many centers use short-term in-
tubation to administer the surfactant followed by rapid extubation 
(InSurE). The other alternative that has become popular in recent 
years is the administration of surfactant through a small tube in-













































































Because of the frequent failure of NCPAP in the smaller and 
sicker infants, an alternative is to use nasal ventilation (NIPPV) 
instead. This mode of support is more effective than NCPAP, re-
ducing the need of intubation in infants with RDS and significant-
ly reducing respiratory failure and the need for reintubation after 
weaning from mechanical ventilation. Despite these short-term 
benefits, the use of NIPPV has not been associated with a consis-
tent reduction in BPD. There are a number of unanswered ques-
tions regarding NIPPV, such as mechanisms of action, importance 
of synchronization, and best indications and settings in different 
disease states.
Another alternative to NCPAP that has gained popularity in 
recent years is high flow nasal cannula (HFNC). This method al-
lows oxygen supplementation while simultaneously generating 
some positive airway pressure. The main advantage of HFNC is 
that it is simple to use and better tolerated by the infant, but it is 
less effective than NCPAP. The main limitations of HFNC are the 
variability in the effective inspired oxygen concentration and in 
the airway pressure delivered. It is also not possible to accurately 
measure these values. Both, airway pressure and effective inspired 
oxygen are determined by the cannula size, the amount of gas flow 
used, and by the respiratory pattern of the infant.
The use of these less invasive modes of respiratory support is 
very effective in larger premature infants where it is associated with 
less need for invasive ventilation and improved outcomes. Unfor-
tunately, in the more immature infants, those under 26-28wks of 
gestation, the less invasive modalities of support commonly fail 
and these infants end up requiring invasive ventilation. These are 
the infants with more severe respiratory failure and with the high-
er incidence of BPD, but because of the severity of their lung dis-
ease, poor respiratory drive and inability to sustain their respira-
tory effort, fail noninvasive support and still require invasive me-
chanical ventilation. This partially explains why the incidence of 
BPD has not decreased in this population.
References
 1 Ali N, Claure N, Alegria X, et al. Effects of non-invasive pressure support 
ventilation (NI-PSV) on ventilation and respiratory effort in very low 
birth weight infants. Pediatr Pulmonol 2007; 42:704–710
 2 González AJ, Quinteros A, Luco M, et al. Hypopharyngeal oxygen con-
centration and pressures delivered by low flow nasal cannula in preterm 
infants: Relationship with flow, gas mixture, and infant’s weight. Pediatr 
Pulmonol 2019;54:1596–1601
 3 Gupta S, Donn SM. Continuous positive airway pressure: Physiology and 
comparison of devices. Semin Fetal Neonatal Med 2016;21:204–211
 4 Ho JJ, Subramaniam P, Davis PG. Continuous distending pressure for 
respiratory distress in preterm infants. Cochrane Database Syst Rev 
2015;4:CD002271
 5 Isayama T, Chai-Adisaksopha C, McDonald SD. Noninvasive ventila-
tion with vs without early surfactant to prevent chronic lung disease in 
preterm infants: A systematic review and meta-analysis. JAMA Pediatr 
2015;169:731–739
 6 Lemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent posi-
tive pressure ventilation (NIPPV) versus early nasal continuous positive 
airway pressure (NCPAP) for preterm infants. Cochrane Database Syst 
Rev 2016;12:CD005384
 7 Liew Z, Fenton AC, Harigopal S, et al. Physiological effects of high-flow 
nasal cannula therapy in preterm infants. Arch Dis Child Fetal Neonatal 
Ed 2020;105:87–93
 8 Manley BJ, Arnolda GRB, Wright MR, et al. Nasal high-flow therapy for 
newborn infants in special care nurseries. N Engl J Med 2019;380:2031–
2040
 9 Manley BJ. Nasal high-flow therapy for preterm infants: Review of neo-
natal trial data. Clin Perinatol 2016;43:673–691
10 Wilkinson D, Andersen C, O’Donnell CP, et al. High flow nasal cannula 
for respiratory support in preterm infants. Cochrane Database Syst Rev: 
2016;2:CD006405
6
Newer Modes of Invasive Conventional Mechanical 
Ventilation
A.H. van Kaam
Department of Neonatology, Emma Children’s Hospital 
Amsterdam UMC, University of Amsterdam, The Netherlands
Although non-invasive respiratory support is increasingly used 
in preterm infants, a large proportion needs to be invasively 
ventilated at some point during their admission [1]. Invasive 
mechanical ventilation (IMV) may be lifesaving, but may also 
result in so-called ventilator-induced lung injury (VILI) which is 
considered an important risk factor in the development of 
bronchopulmonary dysplasia [2]. Furthermore, IMV can cause 
significant patient discomfort. Ideally invasive ventilation modes 
should minimize VILI, by avoiding too high or too low tidal 
volumes (volutrauma) and limiting the presence of atelectasis 
(atelectratuma). Furthermore, mechanical support should be 
synchronized with the spontaneous breathing effort of the infants, 
thereby improving patient comfort.
Historically, newborn infants have been ventilated with time-
cycled pressure limited ventilation (TCPL). During TCPL the end 
of inspiration is time-cycled, the fixed driving pressure results in a 
variable tidal volume delivery depending on the lung mechanics 
and patient effort, and the positive end-expiratory pressure (PEEP) 
is often set a relatively low level. These characteristics of TCPL may 
increase the risk of VILI. Newer modes have been introduced to 
address these limitations.
Volume target ventilation (VTV) modes target a tidal volume 
instead of a fixed driving pressure, thereby reducing the risk of 
volutrauma. Studies have shown that VTV improves patient 
outcomes compared to TCPL ventilation [3]. Proportional assist 
ventilation modes aim to compensate disease related changes in 
compliance and resistance and the resulting increased work of 
breathing. Proportion assist ventilation (PAV) uses flow changes 
and neurally adjusted ventilatory assist (NAVA) uses electrical 
activity of the diaphragm to measure the work of breathing and to 
synchronize the patient effort to the mechanical support [4].[5] 
Although these modes reduce work of breathing and improve 
ventilation synchrony, there is insufficient evidence for benefits on 
important clinical outcomes.
There are several modes under investigation. Airway Pressure 
Release Ventilation (APRV) applies a high constant distending 
pressure for a prolonged time combined with time-cycled releases 
to a lower pressure for a short period of time [6]. Mandatory 
Minute Ventilation (MMV) supports spontaneous breaths and 
estimates at regular intervals the minute volume. If the estimated 
minute volume is below the set target, extra mechanical inflations 
are started to guarantee the preset minute volume [7]. Variable 
Ventilation (VV) tries to mimic the variability of VT and respiratory 












































































present in newborn infants [8]. These newer modes have mainly 
been tested in preclinical studies and are not ready for clinical use.
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Minimally Invasive Surfactant Therapy: Useful or 
Fashionable?
C. Härtel, W. Göpel, E. Herting
Department of Pediatrics, University Hospital of Schleswig-
Holstein, Campus Lübeck, Lübeck, Germany
Minimally-invasive surfactant therapy (MIST; or LISA: Less in-
vasive surfactant administration) is a method to administer surfac-
tant via a thin catheter to spontaneously breathing infants with 
CPAP (CPAP= Continuous positive airway pressure) support [1]. 
Randomized controlled trials and meta-analyses have demonstrat-
ed that MIST is superior to conventional tracheal intubation or 
IN-SUR-E (Intubation, Surfactant, Extubation) for surfactant de-
livery in terms of reducing the need for mechanical ventilation and 
the combined outcome of death and bronchopulmonary dysplasia 
(BPD) [2–4]. Maintenance of spontaneous breathing in combina-
tion with the MIST strategy holds a big promise in the complex 
concept of supporting the individual capacity of a preterm infant 
to adapt to extra-uterine life. Therefore the MIST method meets 
increasing clinical interest worldwide and is now recommended in 
international guidelines for surfactant replacement therapy [5]. 
However, several open questions remain. First, particular indica-
tions and treatment thresholds for MIST in distinct patient groups 
need to be defined and assessed in randomized controlled trials. In 
particular, strategies of prophylactic MIST for extremely preterm 
babies < 27 weeks of gestation have been already employed in 
many units but never been subjected to high-quality trials. Second, 
unpublished observational data from the German Neonatal Net-
work (GNN) are encouraging in terms of better lung function 
(FEV1) and intellectual properties (WPPSI score) in MIST treated 
infants as compared to infants that received surfactant via the stan-
dard route. Recent two-year follow-up data from the AMV trial 
suggest that MIST is a safe strategy, however, the sample size is too 
small to draw warrant conclusions [6]. More research is needed on 
long-term outcome after MIST, and five-year follow-up assess-
ments from AMV and NINSAPP trials are under way. Finally, pa-
tients’ comfort is a strong argument to promote the MIST ap-
proach, but it is still connected with the unpleasant experience of 
laryngoscopy. Therefore positioning during treatment (lateral ver-
sus supine?), optimization of devices/catheters to maintain the lar-
ynx function, and the issue of analgesia/sedation during the pro-
cedure require further study. 
References
 1 Dargaville PA, Aiyappan A, De Paoli AG, et al. Minimally-invasive sur-
factant therapy in preterm infants on continuous positive airway pres-
sure. Arch Dis Child Fetal Neonatal Ed 2013;98:F122–F126
 2 Göpel W, Kribs A, Ziegler A, et al. Avoidance of mechanical ventilation 
by surfactant treatment of spontaneously breathing preterm infants 
(AMV): an open-label, randomised, controlled trial. Lancet 
2011;378:1627–1634
 3 Kribs A, Roll C, Göpel W, et al. Nonintubated surfactant application vs 
conventional therapy in extremely preterm infants: a randomized clini-
cal trial. JAMA Pediatr 2015;169:723–730
 4 Isayama T, Iwami H, McDonald S, et al. Association of noninvasive ven-
tilation strategies with mortality and bronchopulmonary dysplasia 
among preterm infants: A systematic review and meta-analysis. JAMA 
2016;316:611–624
 5 Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines 
on the management of respiratory distress syndrome – 2019 Update. 
Neonatology 2019;115: 432–450
 6 Herting E, Kribs A, Härtel C, et al. Two year outcome data suggest that 
less invasive Surfactant Adminstration (LISA) is safe. Results from the 
follow-up of the randomized controlled AMV (Avoid mechanical Ven-
tilation) Study. Eur J Pediatr 2020, in press.
8
BPD, from Pathogenesis to Prevention: An 
Unresolved Problem
E. Bancalari
Division of Neonatology, University of Miami Miller School of 
Medicine, Miami, FL, USA 
With the introduction of antenatal steroids, surfactant therapy 
and modern respiratory support, the original presentation of 
Bronchopulmonary dysplasia (BPD) described by Northway et al. 
has become uncommon and has been replaced by a milder form. 
Most of these infants are not exposed to high airway pressures or 
inspired oxygen concentrations, the two main insults implicated 
in the pathogenesis of the original BPD. This milder form of 
chronic lung illness known as “new BPD”, is characterized by a 
decreased formation of alveolar septae and capillaries and a simpli-
fied lung architecture with decreased alveolo-capillary surface.
The prevention of BPD is based on avoiding the multiple fac-
tors that contribute to lung injury in preterm infants. The admin-
istration of antenatal steroids and surfactant replacement in in-
fants with RDS improves their respiratory course reducing the 
need for invasive ventilation. Early use of nasal CPAP instead of 
invasive ventilation has been shown to reduce BPD or death. In 
infants who still require mechanical ventilation, minimizing volu-












































































important in preventing lung injury and BPD. Volume-targeted 
ventilation has also been shown to reduce the duration of ventila-
tion and the incidence of BPD. Studies evaluating the use of high 
frequency ventilation have provided inconsistent results in terms 
of BPD. The increased risk of BPD in infants exposed to antenatal 
and postnatal infections stresses the importance of preventing 
perinatal infections to reduce BPD. Closure of a hemodynamically 
significant PDA may also play a role in reducing lung injury and 
the severity of BPD, but the evidence for this is inconclusive. 
Supplemental vitamin A administration to maintain normal 
serum levels has also been shown to reduce the incidence of BPD. 
The use of corticosteroids in ventilator dependent infants im-
proves lung function allowing faster weaning from mechanical 
ventilation and supplemental oxygen. However, their use has been 
associated with worse neurodevelopmental outcome. The optimal 
population to be treated, age of treatment, dose schedule and dura-
tion of therapy have not been clearly established. Recent evidence 
suggests a reduced incidence of BPD in infants treated with tra-
cheal instillation of surfactant and budesonide early after birth. 
Some trials have shown a lower incidence of BPD in infants who 
received hydrocortisone after birth, but this therapy has been as-
sociated with higher rates of intestinal perforation. 
Caffeine use for extubation and apnea was associated with a 
reduced incidence of PDA and BPD in preterm infants. The mech-
anisms for this reduction are not well understood but can be due 
to a shorter duration of mechanical ventilation in infants receiving 
caffeine. While the implementation of the interventions described 
above has resulted in a significant reduction in the incidence of 
severe BPD, the incidence of milder forms of chronic lung damage 
remains high.
Future directions in BPD prevention will be targeted to the 
preservation of normal alveolar and vascular development. Inter-
ventions may include the reduction of different mediators that in-
duce inflammation and inhibit alveolar and capillary formation 
and the possible administration of stem cells as modulators of al-
veolar and vascular development.
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Topical Steroids: Inhaled or Mixed with Surfactant?
D. Bassler, T. Restin, C.M. Rüegger
Department of Neonatology, University Hospital Zurich and 
University of Zurich, Zurich, Switzerland
A substantial number of preterm infants around the world 
(America, Europe, Asia) receive inhaled glucocorticoids for the 
prevention and/or treatment of Bronchopulmonary Dysplasia 
(BPD) in routine clinical care despite the lack of data supporting 
this practice [1, 2, 3]. As a consequence, the Neonatal European 
Study of Inhaled Steroids (NEUROSIS) that investigated the role 
of inhaled budesonide for the prevention of BPD was launched. 
NEUROSIS showed a significant reduction in the incidence of 
BPD [4]. However, the primary outcome (a composite of death or 
BPD at 36 weeks postmenstrual age) was only of borderline sig-
nificance as a result of a non-significant trend to increased mortal-
ity in the budesonide group [4]. Neurodevelopmental disability 
among survivors at a corrected age of two years was a predefined 
secondary outcome [5]. At the time of the follow-up examination, 
this long-term outcome, was 48% in the budesonide and 51% in 
the placebo group (RR: 0.93; 95% CI: 0.80, 1.09; P = 0.40) but post 
hoc results suggested higher mortality with budesonide [5]. No 
plausible explanation had been identified after a detailed review of 
the causes of death and clinical course of all study infants who died 
[4, 5, 6]. In the analyses, no adjustment was made for multiple 
comparisons [5]. 
In a systematic review, all studies in which inhaled glucocorti-
coids were compared to placebo for the prevention or treatment of 
BPD in preterm infants were pooled in various meta-analyses [7]. 
In the inhaled glucocorticoid group, there was a significant benefi-
cial effect on the incidence of BPD at 36 weeks and no effect on 
mortality [7]. The authors of the systematic review concluded that 
inhaled glucocorticoids may be considered for the prevention or 
treatment of BPD [7].
Delivery of glucocorticoids to the periphery of the lungs may 
be facilitated by the aid of other drugs, e.g. by surfactant used as a 
vehicle. In a pilot trial with 116 newborns, Yeh and colleagues 
treated neonates every 8 hours with either 0.25 mg/kg of budesonide 
mixed with 100 mg/kg of surfactant or surfactant alone [8]. Inclu-
sion criteria were very low birth weight (less than 1500 g) and se-
vere respiratory distress with a fraction of inspired oxygen ≥ 0.6. 
The researchers could demonstrate that the combined therapy 
with budesonide and surfactant improved the composite outcome 
of BPD and death.
In the largest RCT published today, the mixture of surfactant 
and budesonide decreased BPD by 21% with a significant effect 
only seen for severe BPD when using the NICHD definition [9]. 
No acute adverse effects and no effect on neurodevelopmental out-












































































In a recent observational study, two time periods were com-
pared in a single center. In the more recent time period, a local 
clinical practice change was introduced to include budesonide 
with surfactant in clinical care. BPD or death did not change be-
tween the historical surfactant cohort and the budesonide cohort. 
However, budesonide was associated with decreased severity of 
BPD, decreased mechanical ventilation use, earlier discharge, and 
similar short-term outcomes [10]. Although the published results 
from controlled clinical trials combining surfactant and glucocor-
ticoids are promising, they should be replicated in large RCTs per-
formed in different settings and countries.
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Why Do Former Preterm Infants Wheeze?
R.J. Martin
Department of Pediatrics, Rainbow Babies & Children’s Hospital/
Case Western Reserve University School of Medicine, Cleveland, 
OH, USA
Longer term respiratory morbidity is a frequent concern for 
former preterm infants. Increased airway reactivity and wheezing 
disorders are extremely common in this population, both in infants 
who meet diagnostic criteria for bronchopulmonary dysplasia 
[BPD], and in the absence of this diagnosis. It is, therefore, 
imperative to gain a better understanding of normal and abnormal 
postnatal development of the immature airway. Airway 
hyperreactivity may be secondary to abnormal bronchoalveolar 
attachment in the face of parenchymal lung injury, or secondary 
to an imbalance between constrictor and dilator neural pathways. 
Finally, the airway itself may undergo functional and/or structural 
changes, including increased airway smooth muscle mass, and 
changes in airway extracellular matrix which may, in turn, 
modulate downstream signaling pathways to hyperoxia or pressure 
exposed vulnerable airways.
In order to characterize biologic mechanisms that contribute 
to airway hyperreactivity in former preterm infants, we and others 
have employed neonatal rodent models that are both immature at 
birth and readily survivable. Of interest is the observation that even 
modest exposure to oxygen [e.g., FiO2 of 0.4] can cause greater 
airway hyperreactivity than severe hypoxia [FiO2 of 0.7] as the lat-
ter can result in apoptosis rather than hypertrophy of airway 
smooth muscle [1]. Application of CPAP to the neonatal mouse 
model also may contribute to increase airway wall thickness and 
enhanced contractility [2, 3]. A novel new line of investigation is 
the role of altered extracellular matrix in the airway and surround-
ing tissues in modulating airway smooth muscle signaling [4].
There is, unfortunately, no evidence that the persistently im-
paired airway function exhibited by former preterm infants is di-
minishing, despite increased use of non-invasive ventilatory strat-
egies [5]. It is unclear how much is contributed to by structural 
versus functional consequences of preterm birth on the immature 
airway. Meanwhile, we must minimize exposure of former pre-
term infants to adverse environmental influences such as smoking, 
as impaired airway function persists well into adulthood in this 
high risk population.
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Follow-Up and Long-Term Respiratory Function 
After Premature Birth
G. Res, L. Moschino, E. Baraldi 
Neonatal Intensive Care Unit, Department of Women’s and 
Children’s Health, University of Padua School of Medicine, 
Padua, Italy
Bronchopulmonary dysplasia (BPD) is the most frequent 
respiratory complication of extremely premature birth. As most 
preterm-born infants survive and reach adulthood nowadays, we 
should start acknowledging preterm birth as a chronic condition 
that requires long-term follow-up. Data from major cohort studies 












































































associated with mortality from infancy to mid-adulthood, with a 
higher risk of cardiorespiratory diseases [1]. Prematurity is 
characterized by an immature stage of lung development. Various 
injuries before and after birth, together with a genetic susceptibility, 
can lead to direct airway and parenchymal damage, inducing a 
deviation from the normal developmental path [2]. Depending on 
the timing and extent of exposure, lung injury may range from 
early developmental arrest to structural damage of a relatively 
immature lung [2], involving smaller airways and lower than 
normal lung volumes [3]. In most studies, survivors of BPD have 
airflow limitation and their FEV1 (a powerful indicator of flow 
limitation on spirometry) does not reach the normally-expected 
optimal peak at 24 years old [4]. Poor lung function early in life 
tracks with a weaker lung function in adulthood, and a higher risk 
of a COPD-like disease [2, 5]. In a recent Australian study, preterm 
infants showed a worrying decline in spirometric values over time, 
with the worst trajectories in BPD survivors [6]. Histopathological 
findings in adolescent BPD survivors confirm BPD as an active 
disease with ongoing airway inflammation [7]. Although the 
young people affected are often treated as asthma patients, the two 
obstructive lung diseases do not share the same pattern of 
inflammation.
A key aspect of better care for extremely preterm babies with 
lung problems is a structured and standardized cardiopulmonary 
follow-up at ambulatory care clinics, identifying the relevant ele-
ments of clinical care, as well as markers of health and disease [8]. 
There are few current recommendations on the long-term moni-
toring and treatment of these children, based largely on a low qual-
ity of evidence. The European Respiratory Society advocates ur-
gent studies to assess the effectiveness of bronchodilators, inhaled 
corticosteroids, diuretics and macrolides in BPD survivors after 
discharge [9]. Standardized lung function tests may be useful for 
understanding changes over time and guiding treatment options, 
but measuring lung function in early life is challenging. Spirometry 
with lung volume and diffusion capacity measurements can be 
performed in older children (from 5 years on) [8].
Since preterm birth may be a previously-underestimated risk 
factor for heart failure in children and young adults, a closer 
follow-up and assessment of this population’s cardiac health may 
be necessary.
All in all, the most effective strategy for preventing long-term 
respiratory and cardiac morbidities in these subjects would be to 
reduce the burden and severity of BPD, and to identify its early 
predictive biomarkers to guide new treatments. Despite advances 
in neonatal intensive care, current strategies (antenatal corticoste-
roids, surfactant therapy and noninvasive ventilation) are scarcely 
effective in preventing BPD. In recent years, treatments with mes-
enchymal stem cells and their secreted extracellular vesicles have 
shown promise [10, 11].
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The Microbiome and the Developing Immune 
System
G. Holländer 
Department of Paediatrics, University of Oxford, UK; University 
Children’s Hospital of Basel, Basel, Switzerland; Botnar Research 
Centre of Child Health, ETH Zurich and University of Basel, Basel, 
Switzerland
The infant’s microbial colonization of internal and external 
surfaces - including the gastrointestinal tract, skin, and oral mucosa 
- is established in a complex, dynamic, and step-wise process and 
will eventually establish a mutualistic relationship with the host’s 
mucosal and systemic immune systems. Both maternal and 
neonatal factors influence in a quantitative and qualitative fashion 
the bacterial colonization and consequently the maturation of the 
immune system, whereby, for example, the mode of delivery, 
breastfeeding, and antibiotics used perinatally as well as gestational 
age have been shown to impact on the richness and diversity of the 
intestinal microbiome. This colonization occurs during a critical 
developmental window and coincides with a possibly time-
restricted phase during which the plasticity of the mucosal immune 
system predisposes to receive microbial instruction as to its own 
differentiation and functional maturation. This interaction is 
initiated within hours after birth and involves originally pioneering 
microbiota of relatively low diversity thought to facilitate bi-
directional host-commensal interactions that establish the immune 
system’s maturity including its tolerance to environmental 
exposures. Indeed, the absence of commensals has profound 
effects on the structural and functional development of the immune 
system, including but not limited to defects in lymphoid tissue 
development within the spleen, thymus, and lymph node. The 












































































microbial composition and complexity in adult life, and when 
disturbed may contribute to the development of microbial states 
that have been associated with disease later in life, including 
inflammatory bowel disease, allergy, and asthma. The presentation 
will review recent findings of the instructive relationship between 
the intestinal microbiome and the immune system of the neonates. 
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Platelet Transfusions: More Harm than Benefit? 
R. Carr
Department of Haematology, Guy’s & St Thomas’ Hospital, 
London; King’s College London, London, UK
Thrombocytopenia in newborn infants admitted to neonatal 
units is common and transfusion of donor platelets to keep the 
platelet count at a safe level to prevent bleeding is frequent, but to 
now there has been little evidence to define what platelet count is 
‘safe’. There are also international differences of opinion on what 
platelet threshold should be used as an indicator for prophylactic 
platelets to be given. A single study, in 1993, randomised preterm 
infants to receive prophylactic platelets at a threshold of either 
150 × 109/l or 50 × 109/l, with no difference in bleeding between 
the two groups [1]. This set 50 × 109/l as the default ‘safe’ threshold 
adopted in the USA, though a more restrictive use of platelets, 
based on lower thresholds, is more common in Europe [2]. While 
platelet transfusion to prevent bleeding is mandatory in some ae-
tiolgies, eg. fetal and neonatal alloimmune thrombocytopenia 
(FNAIT) and generally unnecessary in others, eg. autoimmune 
thrombocytopenia (ITP), the commonest causes of a low platelet 
count, placental insufficiency and infection are not necessarily as-
sociated with a significant bleeding tendency.
Two recent multicentre studies in the UK have provided evi-
dence to define the relationship between platelet count and bleed-
ing risk, and establish an appropriate prophylactic transfusion 
strategy.
The PlaNeT-1 study was a prospective observational cohort 
study in seven regional neonatal intensive care units, which docu-
mented platelet counts and bleeding episodes in all babies whose 
platelet count fell below 60 ×109/l [3]. The major findings were that 
only 9% of infants whose platelet count fell below 20 × 109/l devel-
oped bleeding classified as severe, though some minor bleeding 
was common. The novel finding was that major haemorrhage was 
more associate with gestational age <28 weeks and a platelet count 
<50 × 109/l within the first 10 days. There was no evidence that 
minor bleeding predicted the development of major haemorrhage.
This observational study was followed by a randomised 
therapeutic study, PlaNeT-2, comparing bleeding and mortality in 
infants born at less than 34 weeks, randomised to receive 
prophylactic platelets below a threshold of either 50 × 109/l or 
25 × 109/l. [4]
Infants were enrolled with parental consent following a record-
ed platelet count <100 3 109/l. Of 1,029 enrolled infants, 660 (64%) 
developed thrombocytopenia <50 3 109/l. These were randomised 
equally between the higher and lower threshold groups. In the 
higher threshold group, 90% received at least one platelet transfu-
sion; in the lower threshold group, 53% received at least one trans-
fusion.
The primary outcome was death or major bleeding up to and 
including day 28. A primary outcome event occurred in 26% of 
high threshold subjects and 19% of low threshold subjects (P=0.02). 
There was a significantly higher mortality in those infants ran-
domised to receive platelets at the higher threshold of 50 3 109/l, 
compared to the lower threshold of 25 3 109/l (15% v 10%). There 
was no significant difference in the incidence of bleeding (major 
or minor) between the two groups. 
This large randomised study has provided objective evidence 
that a more restrictive platelet transfusion policy, with a prophy-
lactic transfusion threshold of 25 3 109/l, is safe and does not incur 
a greater risk of major haemorrhage. However, the study unex-
pectedly found a higher mortality in infants randomised to the 
higher threshold and who consequently received more platelets. 
This unexpected finding is unexplained, but poses the question as 
to why more platelet transfusions might tip the balance to greater 
harm than benefit. 
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An Evidence-Based Approach to Neonatal Sepsis: 
Finding a Needle in a Haystack
R.A. Polin
Columbia University College of Physicians and Surgeons, New 
York, NY, USA
Despite the many advancements in neonatal medicine, the 
management of infants with suspected early onset sepsis remains 
a conundrum. Because of the potential risks of increased morbid-












































































antibiotics, even when the probability of sepsis is considered low. 
Unfortunately, the indiscriminate use of antibiotics in the first few 
days of life has been associated with increased mortality (especial-
ly with the use of 3rd generation cephalosporins) and dysbiosis, 
(which may predispose preterm infants to bronchopulmonary 
dysplasia, necrotizing enterocolitis and late onset sepsis). Further-
more, sepsis workups are costly, increase the duration of hospital-
ization and interfere with breast feeding and maternal bonding. 
The traditional approach to sepsis workups involves an assessment 
of risk factors and a careful physical examination. Symptomatic 
infants with risk factors are almost always treated with broad spec-
trum antibiotics. The greatest challenge is deciding how to manage 
infants with suspected sepsis who look well, but who have risk fac-
tors for early-onset sepsis (e.g., chorioamnionitis). Guidelines, 
which recommended treating every infant exposed to maternal 
chorioamnionitis, led to overtreatment of infants who were not 
infected. In late preterm and term infants born to women with 
chorioamnionitis, the risk of sepsis is about 1%. If the infant is well-
appearing at birth, the risk of sepsis is considerably lower. 
The American Academy of Pediatrics, Committee on the Fetus 
and Newborn has recently recommended three strategies for the 
evaluation and management of infants ≥ 35 weeks gestation with 
suspected early onset sepsis [1]. They preface the recommenda-
tions with four guiding principles:
• No single method can be used to identify all infants with early-
onset sepsis with precision
• Each strategy has merits and limitations
• Each strategy must include measures to monitor the infant and 
minimize the duration of antibiotic therapy
• Birth centers should choose a strategy that is best suited to their 
local resources.
The first strategy called categorical risk assessment uses risk 
factor thresholds to identify infants with early onset sepsis. This 
approach recommends treatment of any infant born to a woman 
with chorioamnionitis or who is ill appearing. The limitations of 
this approach are: 1) No clear definition is provided for clinical ill-
ness, 2) It overlooks the difficulty in establishing an accurate diag-
nosis of maternal chorioamnionitis, 3) inconsistent consideration 
is given for intrapartum antibiotics, and 4) no clear guidelines are 
given for an abnormal laboratory test. 
The second strategy called multivariate risk assessment uses a 
sepsis calculator to define risk. This is the most popular approach 
in the United states. The risk of sepsis is calculated based on his-
torical risk factors and clinical signs and the incidence of sepsis. 
Management is based on the estimated incidence (expressed per 
1000 live births). The limitations of this approach are: 1) the sepsis 
calculator will miss a substantial portion of infants with proven 
sepsis (~30%), 2) Infants with an equivocal presentation and a cal-
culated incidence of sepsis ≥ 1/1,000 live births but < 3/1,000 live 
births require a blood culture, but blood cultures have a poor sen-
sitivity in that setting and 3) the definition of an equivocal presen-
tation is likely to overlap with that of a well-appearing infant de-
pending on when the physical examination is done.
The third approach employs serial observations without testing 
in infants who are well-appearing but born to women with risk 
factors for sepsis (including chorioamnionitis). When the infant 
becomes symptomatic, antibiotics are initiated. The limitations of 
this approach are: 1) there are limited data to support this ap-
proach, 2) the hospital has to develop systems to do serial observa-
tions and record them accurately and 3) the assessments will add 
the cost of well newborn care. 
Recommendations: 1. Babies with clinical signs of early onset 
sepsis should receive broad spectrum empirical antibiotics. 2. Well 
appearing late preterm and term infants can be closely observed 
without empirical antibiotics or evaluated using the sepsis calcula-
tor. 3. Limit the duration of antibiotic therapy (36hours) in infants 
who are clinically improved with negative blood cultures.
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How Can We Reduce Brain Injury in Preterm Infants?
D. Edwards
Centre for the Developing Brain, School of Biomedical 
Engineering and Imaging Sciences, King’s College London, 
London, UK
Premature birth carries significant long-term risks. While mor-
tality has been consistently falling even for the most immature in-
fants, there is less sustained improvement in neurocognitive out-
comes: about 10% of survivors develop cerebral palsy; around one 
third have definable cognitive problems; and there is an increased 
rate of many mental health problems, for example a 7x increased 
risk of bipolar disorder. 
The underlying brain injuries that leads to these long-term 
problems are poorly understood. Accounts of preterm brain in-
jury tend to emphasise lesions detected at post-mortem examina-
tion or by neuroimaging such as intraventricular haemorrhage, 
parenchymal infarction, and periventricular leukomalacia. How-
ever, the population incidence of these injuries is too low to ac-
count for the incidence of neurocognitive deficits. Consequently, 
conventional neuroimaging is only partially successful in detecting 
infants who will grow up with long-term problems.
Some of this ‘diagnostic gap’ is due to factors operating beyond 
the perinatal period, and social deprivation is a potent predictor of 
adverse outcomes. Nevertheless, there is now much interest cere-
bral dysmaturation after preterm birth, particularly associated 
with inflammation and oxygen dysregulation. 
Advanced computational imaging has shown a wide range of 
abnormalities in preterm brain growth: thalamic and cortical 
growth in particular are reduced, and white matter and cortical 
microstructure are affected. These abnormalities are widely differ-
ent between infants, and it is clear that some of these changes begin 
before delivery, while genetic imaging methods have discovered 
genetic predispositions to abnormal brain development.
Preterm brain injury is thus complex and poorly understood. 
Experimental and pathologic evidence shows that maturation of 
pre-oligodendrocytes, growth of axons, dendritic arborisation and 
synaptogenesis are all impaired, and that microglia play an impor-
tant role both in modulating normal brain development and in 












































































normal synaptogenesis and in synaptic pruning, and there is in-
creasing evidence that they may play a central role in preterm brain 
dysmaturation.
To date specific interventions that reduce adverse outcomes 
have modest effects. Outcomes can be improved by some thera-
peutic interventions, including maintaining appropriate oxygen 
saturations, magnesium administration before delivery and caf-
feine given after birth. Reducing ex utero transfers of infants re-
duces the incidence of focal brain lesions. Promising interventions 
such as erythropoietin are under investigation, and there are inter-
esting possible benefits to be had by optimising nutritional and 
environmental effects in the neonatal period.
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Monitoring the Neonatal Brain: How, When and For 
How Long?
L.S. de Vries
Utrecht Brain Center, University Medical Center Utrecht, Utrecht 
University, Utrecht, The Netherlands
There is an increasing interest to monitor the neonatal brain. 
In the full-term infant who receives hypothermia for neonatal en-
cephalopathy due to presumed perinatal asphyxia, some centres 
will use amplitude integrated EEG (aEEG) as part of the entry cri-
teria for cooling. Most will use aEEG during cooling and rewarm-
ing and an increasing number of centres are now also using con-
tinuous video EEG. [1] Several seizure detection algorithms have 
become available, improving recognition and allowing for appro-
priate treatment. Continuous use of the EEG will confirm the effect 
of antiepileptic medication and will recognize ongoing electro-
graphic seizures, following uncoupling. [2] Combining aEEG with 
Near Infrared Spectroscopy (NIRS) allows prediction of neurode-
velopmental outcome earlier than the use of aEEG only. [3]
In the preterm infant continuous EEG and NIRS are not yet 
standard of care and are used in neuro-dedicated centres. The in-
cidence of seizures is not yet clear and whether and how to treat 
them is not yet well elucidated. [4] Reduced NIRS values during 
the first 72 hours is predictive of neurodevelopmental outcome. [5]
For both the preterm as well as the full-term infants, neuro-
imaging should also be seen as monitoring the brain. In the full-
term infant with perinatal asphyxia receiving hypothermia and 
any infant with neonatal seizures, MRI should be performed fol-
lowing bed-side ultrasound. [6] In the preterm infant, cranial ul-
trasound is preferred for monitoring development and evolution 
of brain injury. Especially in preterm infants who develop post-
hemorrhagic ventricular dilatation (PHVD) close monitoring with 
ultrasound is indicated and will guide timing of (neurosurgical) 
intervention. [7] At least one MRI at term equivalent age should 
be considered in those with abnormalities recognized on ultra-
sound and the extremely preterm infant with a GA<28 weeks. 
Several studies have now shown that imaging findings at term 
equivalent age predict school age outcome. [8] 
Conclusion: Neuromonitoring should become routine clinical 
care and will play an important role in measuring the effect of neu-
roprotective interventions.
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Analgesic Drugs: Impact on Pain Perception and 
Brain Activity
R. Slater
Department of Paediatrics, University of Oxford, Oxford, UK
Pain experienced during infancy can have long-term negative 
consequences, but is under-treated and poorly understood, repre-
senting a significant clinical problem. For an infant who requires 
hospital treatment, medical procedures are an everyday reality, 
and the youngest and sickest infants may experience more than 50 
procedures per day [1]. Nevertheless evidence-based analgesic 
treatment options are limited and understanding of  the mecha-
nisms that underpin the development of pain perception is poor 
[2]. In this lecture, I will discuss how we can better understand how 
the human infant central nervous system develops to enable us to 
experience and modulate pain, and to use this understanding to 
develop new analgesic treatment options for infants. 
One approach to solving these research challenges is to com-
bine clinical neuroscience with novel analytical methods to im-
prove understanding of infant brain development, and to translate 
this knowledge into the design of new clinical trials to test the an-
algesic efficacy of pain treatments. This is an important step, be-
cause until relatively recently, this field was characterised by out-












































































infants cannot feel pain). However, recent scientific and techno-
logical advances in human imaging provide an opportunity to gain 
insight into how immature structural and functional brain archi-
tecture influences the development of pain-related brain activity 
and behaviour [3, 4].
Using near-infrared spectroscopy, functional magnetic reso-
nance imaging (fMRI) and electroencephalography, I will show 
how we can use these methodological approaches to measure pain-
related brain activity in infants [5]. I will describe fMRI studies in 
newborn infants that show that evoked patterns of pain-related 
brain activity are similar to adults, with brain areas associated with 
emotional aspects of adult pain also active in infants. I will discuss 
how this work has led to the development of brain-derived mea-
sures that are validated in both premature and term-born infants, 
sensitive to analgesic administration, and which have been used in 
a clinical trial to assess the analgesic benefits of pharmacological 
interventions [6]. A direct example of how this work can lead to 
healthcare benefits will be highlighted in the Poppi (Procedural 
Pain in Premature Infants) trial, where we established that the use 
of oral morphine at a dose of 100 μg/kg (a dose recommended in 
current national formularies and used clinically on our neonatal 
unit) is not appropriate to treat pain evoked by retinopathy of pre-
maturity screening in non-ventilated infants [7]. 
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The Use of Opioids in the NICU: Navigating Between 
Scylla and Charybdis
J.N. van den Anker
Pediatric Pharmacology and Pharmacometrics, University of 
Basel Children’s Hospital, Basel, Switzerland; Division of Clinical 
Pharmacology, Children’s National Hospital, Washington,  
DC, USA
Analgesic dosing regimens including the choice of drug (e.g., 
opioids, acetaminophen, NSAIDs) should take into account the 
severity and type of pain, the therapeutic window of the analgesic, 
but also the age or developmental state of the (pre)term new- 
born [1-4]. Translation of these concepts into safe and effective 
pharmacological analgesia in neonates necessitates thorough un-
derstanding of the principles of clinical pharmacology. Growth, 
weight or size and maturation or age evolve and profoundly affect 
pharmacokinetics (concentration-time profile, absorption, distri-
bution, metabolism and excretion) and pharmacodynamics 
(concentration-effect profile, objective assessment).
Inadequate management of pain in (pre)term neonates alters 
and affects thresholds of pain, pain or stress-related behavior, 
physiological responses, and contributes to impaired neurodevel-
opmental outcome [5]. 
Alterations in biological covariates (e.g. peripheral and central 
somatosensory function and modulation, brain structure and con-
nectivity) and psycho-social covariates (e.g. gender, coping style, 
mood, parental response) that affect pain perception and expres-
sion were identified in former preterm neonates [5]. Consequent-
ly, effective analgesia is relevant not only because of ethical reflec-
tions or human empathy, but it is a crucial and integral part of 
medical and nursing care to neonates. 
In the (pre)term newborn, it seems that the limbic system here-
by has a specific vulnerability for overexposure to pain, stress or 
drugs (narcotics, analgesics, or sedatives). This is likely because the 
maturational changes in the limbic structures evolve at a very fast 
rate throughout the last trimester of pregnancy until late infancy. 
The limbic system, hippocampus and the regions connected to the 
hippocampus are essential as switch board to encode, consolidate 
and retrieve memory. Intriguingly, these types of memory deficits 
are frequently observed in former preterm neonates [6].
However, there is also emerging evidence on the relation be-
tween the exposure to narcotics and impaired neurodevelopmen-
tal outcome, resulting in a Catch-22 scenario [6]. Experimental 
data from animals provide evidence that chronic morphine expo-
sure in perinatal life results in a reduced brain volume, decreased 
neuronal packing density, and less dendritic growth and branch-
ing. This is associated with learning and motor disabilities. It is, 
however, currently too early to blame these findings purely on the 
use of opioids [7].
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Preventive Strategies, Prediction and Up-To-Date 
Treatment of Severe ROP
A. Hellström, A.-L. Hård
Department of Ophthalmology, Institute of Neuroscience and 
Physiology, Sahlgrenska Academy, University of Gothenburg, 
Gothenburg, Sweden
Retinopathy of prematurity (ROP) is a major cause of prevent-
able blindness worldwide. Preventive strategies aim to promote 
normal growth of retinal blood vessels through oxygen control, 
optimisation of nutrition including critical long chain polyunsatu-
rated fatty acids arachidonic acid and DHA, provision of raw ma-
ternal breastmilk [1] and preservation of fetal haemoglobin [2]. In 
addition, the role of the beta-blocker propranolol in preventing 
progression of ROP is investigated [3].
With current ROP screening less than 10% of screened infants 
need treatment [4]. Prediction models based on birth charac-
teristics, postnatal weight gain and other factors have been devel-
oped to reduce examinations in low-risk infants. A model based 
on advanced statistics using birth characteristics only, from 
more than 7000 infants registered in the Swedish ROP registry 
(SWEDROP) has recently been published and appears to predict 
total risk of ROP-treatment as well as models including weight 
measurements [5]. Surprisingly, treatment risk peaked at 12 weeks 
of age independent of gestational age at birth. Another new vali-
dated prediction model based on daily weight gain demonstrated 
high sensitivity suggesting a 30% reduction in the number of 
infants needing screening [6]. Based on ten-year SWEDROP data 
[7] screening will be changed in Sweden 2020 to include only 
infants with a gestational age of <30 weeks and to postpone the first 
examination to 6 weeks postnatal age in infants born at > 26 weeks. 
This will reduce the number of infants screened in Sweden with 
approximately 20%.
Laser therapy is the method of choice for severe ROP. Anti-
VEGF therapies are implemented worldwide despite insufficient 
knowledge of choice of drug, dosage and long term systemic ef-
fects. There are still concerns regarding the systemic effects on co-
morbidities and neurodevelopmental outcome with the use of 
Anti-VEGF [8, 9]. In the multicentre Rainbow trial the effects of 
the Anti-VEGF drug Ranibizumab (Lucentis®) on ROP treatment 
were compared with laser without demonstrating any significant 
differences [10]. There was a trend for Lucentis superiority regard-
ing favourable ocular outcomes although with a higher risk of re-
currence. Lucentis was approved for the indication of treating se-
vere ROP in October 2019. Long-term follow-up of the Rainbow 
study is on its way.
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Hypoxic-Ischemic Episodes: A Hidden Risk for Brain 
Damage of Very Immature Preterm Infants?
R.J. Martin
Department of Pediatrics, Rainbow Babies & Children’s Hospital/
Case Western Reserve University School of Medicine, Cleveland, 
OH, USA
Non-invasive, continuous oxygen monitoring, with its origins 
in the mid-1970s, first allowed us to document the high incidence 
of intermittent hypoxic [IH] episodes. However, it is only over the 
last decade that increasing attention has been drawn to the poten-
tial longer term consequences of IH [1]. It is now clear that the 
magnitude of these episodes results from a combination of imma-
ture respiratory control superimposed upon an immature lung.
Immature neural maturation that characterizes preterm birth 
can be adversely impacted by IH in various ways. One example is 
retinopathy of prematurity [ROP] where unique characteristics of 
hypoxic episodes play an important contributing role [2]. Another 
is the potential longer term effects of IH in the neonatal period on 
sleep disordered breathing in former preterm infants [3]. Elegant 
neonatal rodent studies clearly support a longer term effect of IH 
on stability of respiratory control.
Persistence of apnea of prematurity has consistently been as-
sociated with poor neurodevelopmental outcome. While such as-
sociations are not necessarily causal, an increasing body of evi-
dence is emerging. Poets has documented that prolonged hypoxic 
episodes of at least one minute’s duration were associated with 
adverse 18 month outcomes [late death or disability, including 
ROP] [4]. We have observed that shorter IH events of at least 20 
seconds’ duration adversely impacted survival, especially in the 
face of intrauterine growth restriction [5]. A high incidence of IH 
events also predicts subsequent development of bronchopulmo-
nary dysplasia [BPD], a well-known association of neurodevelop-
mental disability [6].
There is, therefore, a compelling need to characterize which 












































































are predictors of adverse outcomes. Similarly, the underlying 
mechanisms [oxidative and/or inflammatory pathways] need to be 
elucidated if appropriate intervention strategies can be initiated.
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Neonatal Jaundice: A Puzzle Still Unresolved
T.W.R. Hansen
Division of Paediatric and Adolescent Medicine, Institute of 
Clinical Medicine, University of Oslo, Oslo, Norway
Neonatal jaundice (NNJ) is perhaps the neonatal transitional 
process that most commonly requires medical assessment and 
therapy [1]. Factors that increase unconjugated bilirubin (UCB) 
production, or inhibit/delay its hepatic excretion, may cause path-
ological jaundice [2]. Very elevated serum UCB (TSB) levels can 
lead to severe brain damage, kernicterus spectrum disorder (KSD) 
[3]. KSD is rare in industrialized countries, but now often involves 
infants discharged from the nursery whose readmission to hospital 
for emergency NNJ treatment was delayed. In LMICs KSD re-
mains one of the most common causes of brain damage in new-
born infants [4]. NNJ was described centuries ago, but many as-
pects of NNJ and its treatment remain “a puzzle still unresolved”.
UCB is at the same time both a physiologically important 
antioxidant and a potential toxin [5, 6]. We really do not know how 
these two characteristics balance or compete in brain. UCB is 
potentially toxic to the brain because in its predominant isomeric 
form in serum, IXα (Z,Z), it behaves as lipid soluble and is able to 
cross the blood-brain barrier (BBB) and enter the brain [7]. 
However, its brain entry appears to be modulated by membrane 
transporters, and we need to learn more about the identities and 
characteristics of these ‘flippases’, particularly whether such 
transporters could be pharmacologically upregulated to impede 
UCB entry into, or facilitate its clearance from, brain [8].
Inhibitory effects of UCB have been found in many biological 
systems and reactions, but there is no agreement on ‘the basic 
mechanism of UCB toxicity’. Inhibition of protein phosphoryla-
tion is a common theme in many reactions inhibited by UCB (7), 
but UCB could also be a ‘promiscuous inhibitor’ and the many in 
vitro observations may not reflect what goes on in vivo [9]. Iden-
tifying a basic mechanism might open the door to rescue interven-
tions in infants acutely threatened by UCB neurotoxicity.
Phototherapy (PT is the most common therapeutic interven-
tion in NNJ, converts UCB to more polar isomers, and lowers TSB 
by facilitating UCB excretion into bile and urine. However, con-
version of UCB to photoisomers (PI) may have another salutary 
effect beginning as soon as PT starts [9]. Because PIs are water 
soluble they should be less able to cross the BBB than IXα (Z,Z), 
thus potentially creating an equilibrium shift to drive UCB out of 
the brain. This hypothesis makes theoretical sense, but still needs 
in vivo experimental verification. Side effects of PT have been re-
ported, both short- and long-term, which point to the need for 
more studies to clarify the relative roles of irradiance, spectral pow-
er, duration, and wavelength as far as optimizing the therapeutic 
effect while minimizing side effects/toxicity. 
UCB oxidation may contribute to its clearance from brain 
[8, 9], but we need to identify the enzyme(s) as well as to verify 
whether the oxidation products are non-toxic. Several genetic vari-
ants modulate production and excretion of UCB and thus influ-
ence the risk for KSD [10]. Testing for genetic risk may need to 
become part of a comprehensive pre-discharge risk evaluation that 
should probably also include aspects of the health care delivery 
system and its preparedness for ‘crash cart’ management of infants 
with extreme NNJ. These aspects also need further study.
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Outcome into Adulthood for Our Most Immature 
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Over the past 25 years we have seen an explosion in what we 
understand about long term outcomes particularly for the ex-
tremely preterm individuals now entering adult life. Although 
much is centred on neurodevelopment, prematurity is a pervasive 
problem for development affecting multiple organ systems both in 
the neonatal period and subsequently, and the implications for 
adult life are only now becoming apparent. Pioneering work by 
Maureen Hack [1] and Saroj Saigal [2, 3] is now maturing as we 
start to understand the implications of our childhood observations 
and impact that very preterm or extremely preterm birth has on 
the survivors.
We have followed the EPICure cohort of individuals born in 
1995 at less than 26 weeks of gestation through to 19 years of age. 
The use of longitudinal data allows the determination of trajecto-
ries for the evolution of a range of functions. Using statistical 
methods to account for loss to follow up we can demonstrate that 
from 6 to 19 years cognitive scores remain remarkedly constant 
and do not show significant change as the children grow up or in 
relation to reference scores. [4] Work from the Bavarian Longitu-
dinal study of very preterm children shows similar findings but the 
trajectory of preterms appears less variable than that of term con-
trols. [5]
The preterm child has a common behavioural phenotype, 
namely a constellation of inattention, internalising behaviours and 
deficits in social cognition. [6] Although these appear much great-
er at school age, by adult life (and using self-report) differences as 
young adults appear to be less. [7] Nonetheless the population 
prevalence of psychiatric disorders related to this phenotype, 
namely anxiety, depression, ADHD, and ASD appear to be elevat-
ed in preterm populations in a dose dependent fashion. [8] 
Cognitive impairment over school age leads to lower levels of 
attainment and qualifications as a group, with fewer individuals 
graduating from college. In turn this leads to lower paid positions 
and reduced lifetime wealth. However, much of the differences 
seen in comparison to term-born peers may be explained by the 
excess of neurosensory impairments found in these now historic 
populations. [3] In addition, the behavioural phenotype mitigates 
against high peer pressure leading to fewer risk-taking behaviours, 
such a recreational drugs, smoking and alcohol leading to lower 
degrees of sociopathy.
Further work is required to establish the effect on other organ 
systems, such as the respiratory and cardiovascular systems, and 
to understand the implications of these findings for ageing.
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Preterm Nutrition in 2020: Breast Milk, Probiotics 
and Other Components 
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The mainstay of preterm nutrition in 2020 is a baby’s mother’s 
own milk. But other than for this universal agreement, there is 
controversy about almost every other aspect. There are many ques-
tions that urgently need to be answered. Should pasteurised hu-
man donor milk or formula be used if there is insufficient mother’s 
milk? Does mother’s milk require routine macronutrient fortifica-
tion? Do probiotics and bovine lactoferrin protect against necro-
tising enterocolitis (NEC) and sepsis? Should preterm formula be 
enriched with long-chain polyunsaturated fatty acids? Do very 
preterm babies require nutrient enriched follow-on formulae? 
Sadly, we still do not have reliable answers to any of these ques-
tions. 
In preterm infants, feeding with formula compared with donor 
breast milk, either as a supplement to maternal expressed breast 
milk or sole diet, does not show an effect on allcause mortality, or 
neurodevelopment [1].  Two large well conducted randomised 
controlled trials (RCT) of bovine lactoferrin have failed to confirm 
promise indicated by a meta-analysis of small studies [2]. Current 
evidence does not support the use of human milk fortification [3], 
nutrient enriched post-discharge [4], protein hydrolysate [5] or 
LCPUFAsupplemented formula [6]. 
A 2014 systematic review and meta-analysis concluded enteral 
probiotics reduces severe NEC and all-cause mortality in preterm 
infants though noting that RCT were highly variable with regard 
to birth weight, gestational age, baseline risk of NEC, timing, dose, 
probiotic strain and feeding regimen [7]. To-date enteral probiot-
ics have been evaluated in over 46 RCT, all but two [8, 9] of which 
were small and underpowered to detect important outcomes. Of 
the two large RCT, the ProPrems trial involving Bifidobacterium 
infantis, Streptococcus thermophilus and Bifidobacterium lactis 
showed no difference in the primary outcome, sepsis [8], or all-
cause mortality but did find a reduction in the secondary outcome 
NEC (Bell stage 2 or more). The second large trial, PiPs, with the 
Bifidobacterium breve showed no significant difference in the three 
primary outcomes, NEC (Bell stage 2 or more), sepsis and all-cause 












































































was often reported as a secondary or composite outcome. This is 
an important consideration because secondary outcomes are 
prone to both type one (“false positive” results) and type two errors 
(“false negative” results). Trials are usually designed to have statis-
tical power to detect a difference in the primary outcome but are 
underpowered to detect differences in secondary outcomes. Re-
porting many secondary outcomes increases the risk that a “statis-
tically significant” p-value will be identified by chance. 
What can be done to resolve these important, continuing 
uncertainties? The plethora of “expert-opinion” or “consensus-
opinion” based guidelines are unhelpful. Indeed they risk harming 
babies by the universal imposition on all infants of clinical practices 
that are not evidenced based. There are many lessons from the past 
that should have taught us the dangers of care dictated by expert 
opinion, rather than evidence. The only rational way forward is for 
neonatologists to collaborate to test these uncertainties in high-
quality, properly powered, international RCT. 
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During the first weeks of life, premature neonates are at highest 
risk of developing nutritional deficits. These nutritional deficits 
may reach a daily shortage in energy and proteins in comparison 
to the recommended dietary intake [1]. Providing essential nutri-
ents to low birth weight infants during the early postnatal period 
is critical for adequate growth and neurodevelopment. Malnutri-
tion in all kinds of species leads to neurodevelopmental impair-
ment but slow growth (which does not equal malnutrition) is re-
lated to longevity [2, 3] Reduction of malnutrition rates results in 
higher postnatal growth rates and is associated with favorable long 
term neurodevelopmental outcome [4–6]. Supplementation of 
amino acids has shown to improve protein balance by increasing 
protein synthesis, improves anti-oxidant defense system [7] and 
can potentially prevent catabolic state and neonatal growth retar-
dation [8]. On the other hand, studies in critically ill neonates, 
older children and adolescents have shown that parenteral nutri-
tion during the first week may result in adverse outcomes, such as 
an increase infections and in ventilation days [9, 10]. Especially the 
provision of amino acids increased the likelihood of acquiring a 
new infection, while the likelihood of earlier live weaning from 
mechanical ventilation and the likelihood of earlier live PICU dis-
charge was lower. By contrast, more glucose during the first 3 days 
of PICU stay was independently associated with fewer infections. 
Risk of harm with amino acids was also shown for low doses. This 
has led to a shift in the thoughts about providing parenteral nutri-
tion, although these results have only been shown in term infants. 
Nevertheless, the most recent guidelines, published by the ESP-
GHAN, ESPR and ESPEN and the Chinese brand of the ESPEN 
have worded their recommendations more carefully than the pre-
vious ones, stating that for term infants withholding parenteral 
nutrition during the first week may be considered [11]. A similar 
trial in preterm infants is not yet planned. The question is whether 
stable preterm infants benefit from withholding parenteral nutri-
tion; most likely they do not. However, in case of severe and acute 
NEC or severe sepsis, one can consider withholding especially ami-
no acids also for preterm infants. Amino acids may hamper au-
tophagy during critical illness which in its turn may worsen he-
patic mitochondrial damage and dysfunction [12]. Again, it should 
be stressed, no data are available to support this hypothesis in pre-
term infants, neither is there any insight to for as long such a pe-
riod should last. A large multicenter trial should be planned to 
answer this important question. 
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How to Manage Postnatal Growth Failure?
W.W. Hay, Jr.
University of Colorado, Denver, CO, USA
According to the American Academy of Pediatrics, “Current 
recommendations for parenteral and enteral nutrition are designed 
to provide nutrients to approximate the rate of growth and 
composition of weight gain for a normal fetus of the same 
postmenstrual age and to maintain normal concentrations of 
blood and tissue nutrients.” Unfortunately, most preterm infants 
do not grow after birth for many days, even after early postnatal 
water balance adjustments in total body weight; they don’t keep up 
with intrauterine growth rates after they do start growing; and thus 
they end up growth restricted by term. A principal reason for this 
failure to achieve desired postnatal growth is inadequate nutrition, 
as evidenced by cumulative deficits in energy and protein [1]. 
While some recent observations indicate that with more optimal 
nutrition we are doing better [2], others indicate that at least half 
of these very preterm infants still demonstrate postnatal growth 
failure, much of which is severe [3, 4]. Even today we still are not 
achieving nutritional goals by the end of the first week of life, 
despite the critical developmental stage of these very preterm 
infants [5].
More optimal nutrition of very preterm infants rests on sev-
eral basic principles [6, 7, 8]. Metabolic and thus nutritional re-
quirements do not stop with birth, and the metabolic and nutrient 
requirements of the very preterm infant are equal to or greater than 
those of the fetus of the same gestational age. Thus the preterm 
infant should receive nutrients that at least match what the fetus of 
the same gestational age receives. Furthermore, the smaller the in-
fant, the lower the amount of nutrient stores that are available for 
metabolic needs. As a result, parenteral (IV) nutrition is always 
indicated when metabolic and nutritional needs are not met by 
enteral feeding. IV nutrition should start right after birth to match 
the relatively continuous supply of nutrients that the fetus receives. 
Starting maternal or donor milk as soon after birth as possible and 
advancing enteral nutrition more quickly (20-30 ml/kg/day) have 
successfully maintained gestational age appropriate nutrient in-
takes and have allowed weaning off IV nutrition sooner, reducing 
adverse effects of hyperglycemia and central line associated bacte-
rial systemic infection. Milk feedings reduce the incidence of NEC 
and prolonged milk and breastfeeding promote neurodevelop-
ment. Early protein losses are minimized and positive nitrogen/
protein balance is promoted by providing ~70-80 (IV) to ~90-110 
(enteral) kcal/kg/d of total energy and 3-4 g/kg/d of amino acids. 
Protein is fundamental for growth, but it particularly improves 
growth of the brain and body lean mass. Growth of length is di-
rectly associated with better neurodevelopmental outcomes [9]. 
Excess protein, >4 g/kg/day, does not enhance and may harm de-
velopment, and excess energy intake (>120 Kcal/kg/day) clearly 
leads to development of obesity [10]. 
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Caffeine is an alkaloid that is naturally found in a variety of 
plants, such as tea and coffee and it belongs to a group of purine 
alkaloids called methylxanthines [1]. Methylxanthines stimulate 
the central nervous system, stimulate cardiac muscle, promote 
diuresis and relax smooth muscle [1]. Using caffeine as a therapeutic 
agent in neonatology became widespread after the results of the 
international Caffeine for Apnea of Prematurity (CAP) trial were 












































































without neurodevelopmental disability at a corrected age of 18 
months is improved if apnoea of prematurity is managed without 
caffeine in infants at a high risk of apnoeic attacks [3]. The CAP 
trial showed that neonatal caffeine therapy reduces the risk of 
bronchopulmonary dysplasia and decreases the incidence of 
cerebral palsy and cognitive delay at 18 months [3, 4]. The median 
age of starting study medication in the CAP trial was 3 days and 
the median age of stopping caffeine was 34.4 weeks postmenstrual 
age (pma) [3]. Neonatologists now wonder whether caffeine 
started earlier than 3 days and given longer than 35 weeks pma 
further improves health outcomes. 
Since then multiple studies have attempted to address the op-
timal timing of caffeine administration. A recent observational 
study from the Canadian Neonatal Network that analyzed 2108 
preterm infants <29 weeks’ gestation concluded that early (within 
2 days of birth) caffeine therapy is associated with better neurode-
velopmental outcomes compared with late caffeine therapy [5]. 
Based on this study and a systematic review that includes, amongst 
others, observational studies comparing early versus late caffeine 
therapy in preterm neonates [6], the European consensus guide-
lines on the management of respiratory distress syndrome recom-
mend that “early caffeine should be considered for babies at high 
risk of needing mechanical ventilation such as those on non- 
invasive respiratory support”. [7].
But what about the duration of caffeine treatment and extending 
caffeine treatment beyond 35 weeks pma? A recently published 
observational study evaluated the effect of duration of caffeine use 
on long-term neurodevelopmental outcomes at 3 years corrected 
age in preterm infants with birthweights ≤ 1250 g and concluded 
that the duration of caffeine use in premature infants does not 
impact on long-term outcomes at 3 years corrected age [8]. A 
randomized controlled trial (RCT) in which 98 preterm infants 
were assigned to either an extension of caffeine treatment or to 
usual care, showed that intermittent hypoxia can be reduced by 
extended caffeine treatment but no information on the clinically 
more relevant long-term neurodevelopmental outcome was 
provided [9]. Thus, until more information from well conducted 
RCTs becomes available, a reasonable suggestion may be to follow 
the instructions from the CAP trial in which the study drug was 
discontinued permanently at the discretion of the local clinicians. 
Furthermore, CAP recommended “to continue therapy with the 
study drug until the infant had tolerated at least five consecutive 
days without the use of positive airway pressure” [3].
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Pre- and Post-Natal Steroids: A Critical Appraisal
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Antenatal corticosteroids – current issues: A single course 
of antenatal corticosteroids in women at risk of preterm birth may 
accelerate fetal lung maturation and significantly reduce the inci-
dence of RDS, IVH, NEC, late sepsis and mortality [1]. No clear 
effect has been demonstrated in randomized trials regarding BPD 
or neuro-developmental outcome although a recent cohort study 
did identify increased risk for behavioral or psychiatric problems 
in childhood [2]. In addition, long term follow-up at age 29-36 
years in a Canadian cohort who had been exposed to corticoste-
roids in utero revealed increased risk for anxiety and depression 
[3]. Debate continues regarding the relative benefits and risks of 
repeated courses given to women at ongoing risk of preterm birth. 
A new individual participant data meta-analysis of single vs. mul-
tiple studies included 11 trials with 5,915 infants [4]. Multiple 
courses were associated with a modest reduction in need for respi-
ratory support, but also potentially adverse effects on weight and 
blood pressure.
In an era of expanding indications for antenatal corticosteroid 
administration such as late prematurity, peri-viability and even 
elective cesarean section, we must weigh documented benefits 
against the potential for adverse effects. In this context, it is worth 
noting that very little information is available regarding the most 
appropriate dosing regimen for antenatal corticosteroids. Indeed, 
recent studies in sheep have shown that low dose betamethasone 
acetate is as effective as the routine, combined betamethasone 
phosphate-acetate preparation (Celestone) or dexamethasone in 
inducing fetal lung maturity, as measured by surfactant protein 
mRNAs and mechanical lung properties [5]. Further research may 
allow for individualized use of this powerful intervention.
Postnatal corticosteroids – enduring questions: Early post-
natal systemic dexamethasone ameliorates BPD, while increasing 
risk for adverse neurodevelopmental outcome. Accordingly, their 
use is routinely limited to infants with moderate-severe BPD in 
whom the balance of effects appears more to be positive [6]. As an 
alternative, hydrocortisone has been studied recently in RCTs in-
cluding the Premiloc trial that showed a modest benefit in surviv-
al without BPD and no significant effect on neurodevelopmental 
outcome [7]. The Stop-BPD trial failed to show similar short-term 












































































underway [8]. The combination of surfactant with budesonide has 
shown positive effects in two RCTs and a number of trials of this 
promising approach are underway [9]. Inhaled corticosteroids 
may also offer improvement in BPD although mixed results have 
been reported regarding mortality risk [10]. The search for a mag-
ic bullet to prevent the scourge of BPD races on.
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Stem Cells: The Magic Cure for BPD and Brain 
Damage?
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Advances in perinatal medicine have allowed the survival of 
remature infants at the limit of biological viability. As a conse-
quence, prevention of the ever more immature lung and brain have 
become more challenging [1]. Next generation therapies that en-
able both, injury prevention/repair and proper organ development 
are required to substantially impact outcome of extreme prematu-
rity. Stem cell-based therapies offer a new hope in preventing or-
gan damage in extreme preterm infants [2]. Preclinical studies 
have demonstrated the lung and brain protective effects of exog-
enous administration of a variety of cell therapies in animal mod-
els of disease [3]. Mesenchymal stromal cells (MSCs), identified 
over 40 years ago in the bone marrow as niche cells crucial for the 
proper functioning of hematopoietic stem cells, have advanced to 
the forefront of cell-based therapies. Contrary to the initial hy-
pothesis, cell engraftment and differentiation do not contribute to 
the repair mechanism. Instead, MSCs seem to orchestrate the re-
pair process by cell-cell contact, modulate the immune response 
and release factors that promote lung and brain growth [4]. Early 
phase clinical trials, fuelled by these promising preclinical studies, 
have begun and indicate feasibility and absence of toxicity in a 
small number of extreme preterm infants [5]. While the enthusi-
asm in the neonatal community is palpable, major knowledge gaps 
remain. In parallel to well-designed early phase clinical trials based 
on robust rationale, laboratory research is needed to better under-
stand the biology of MSCs and other putative repair cells, develop 
reliable potency assays that predict therapeutic efficacy, and enable 
the manufacturing of high quality, safe and efficient cell products. 
Maintaining the appropriate balance between discovery and 
evidence-based approach will be critical for cell therapies to fulfil 
their promise in substantially improving the outcome of extreme 
preterm infants without repeating past errors.
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Patent ductus arteriosus (PDA) is one of the most frequent 
diagnoses made in very preterm neonates. Diagnosis and manage-
ment of PDA remains controversial 40 years after the first random-
ized clinical comparing prophylactic surgical ligation versus med-
ical management of a moderate to large PDA in preterm infants 
<29 weeks’ gestational age (GA). [1] Major changes have happened 
since this study including increase in the use of antenatal steroids, 
surfactant therapy for respiratory distress syndrome, routine use 
of echocardiography to diagnose PDA and changing patient popu-
lation characteristics, like, the extremely low birth weight (ELBW) 
infants with PDA. Prolonged patency of PDA has been shown to 












































































dysplasia (BPD), intraventricular hemorrhage (IVH), retinopathy 
of prematurity (ROP), necrotizing enterocolitis (NEC), and in-
crease in mortality in preterm infants. [2] However, recent studies 
have shown no increase in morbidities, like, BPD, ROP, NEC or 
death. [3] Medical care of ELBW infants has also evolved over time 
with fluid restriction, diuretics and early pharmacological treat-
ment of “symptomatic” PDA. Diagnosis of PDA is often made 
based on clinical signs and symptoms, like, active precordium, 
bounding pulses, heart murmur, wide pulse pressure, evidence of 
pulmonary over-circulation, hypotension needing inotropes, and 
low urine output. Typical echocardiographic criteria for a hemo-
dynamically significant PDA (hsPDA) include ductal diameter 
>1.5 mm, low left ventricular output (<200 ml/kg/min), diastolic 
flow reversal in the descending aorta, absent or reverse diastolic 
flow in either superior mesenteric artery or middle cerebral artery, 
and myocardial dysfunction. Pocket echocardiography systems 
(PES) are available to make the diagnosis of PDA in many centers. 
Bedside near infrared spectroscopy (NIRS) monitoring has also 
been used to diagnose hsPDA in preterm infants. [4] Despite the 
improvements in perinatal care practices, several RCTs with phar-
macologic closure of PDA have shown no short- or long-term ben-
efits when compared with “watch and wait” approach. Other issues 
are lack of consensus on what constitutes a hsPDA and estimating 
shunts or effects of PDA on cardiac or lung function and on sys-
temic circulation, more specifically, on cerebral circulation. Surgi-
cal treatment is associated with poor neurodevelopmental out-
comes when compared to medically managed PDA. In spite of the 
many controversies surrounding PDA management, newer mini-
mally invasive surgical techniques, like, trans-catheter closure of 
PDA has been approved by FDA for use in preterm infants >700 g 
with a postnatal age ≥3 days. [5] 
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